GO:2001311 lysobisphosphatidic acid metabolic process: Lysosomal Lipid Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001311 describes the chemical reactions and pathways involving lysobisphosphatidic acid (LBPA), also known as bis(monoacylglycero)phosphate (BMP), a unique lysosomal phospholipid with a phosphodiester linkage and two additional fatty acids.
• LBPA/BMP is synthesized by the Batten disease protein CLN5 and by PLD3/PLD4, which produce the S,S-stereoisomer essential for lysosomal lipid degradation.
• LBPA/BMP is degraded by the phospholipase PLA2G15, and targeting this hydrolase ameliorates lysosomal disease phenotypes.
• Defects in LBPA/BMP metabolism are linked to lysosomal storage disorders, neurodegeneration, and Parkinson's disease–relevant lipid dysregulation.
• LBPA/BMP is required for lysosomal function, including lipid degradation and membrane integrity, and its dysregulation contributes to disease pathogenesis.
• Research on GO:2001311 uses CRISPR knockout, point mutation, knock-in, and overexpression models combined with lipidomics, imaging, and transcriptomics to dissect gene function.
Description
Lysobisphosphatidic acid (LBPA), also known as bis(monoacylglycero)phosphate (BMP), is a structurally unusual phospholipid found predominantly in late endosomes and lysosomes. Unlike typical phospholipids, LBPA/BMP contains a phosphodiester moiety linked to positions sn-1 and sn-1' of glycerol, with two additional fatty acids esterified to the glycerol head group. This unique architecture confers resistance to phospholipases and enables specific roles in lysosomal membrane dynamics and lipid catabolism. The Gene Ontology term GO:2001311, lysobisphosphatidic acid metabolic process, encompasses the chemical reactions and pathways involving this lipid, including its synthesis, remodeling, and degradation. Understanding this process is critical because LBPA/BMP is essential for lysosomal function, and its dysregulation is implicated in lysosomal storage disorders, neurodegeneration, and autoimmune conditions. Recent studies have identified key enzymes in LBPA/BMP metabolism, such as the synthase CLN5 and the hydrolase PLA2G15, providing mechanistic insights and therapeutic targets. This article synthesizes current knowledge on GO:2001311, highlighting genes, mechanisms, disease links, and research methodologies for biomedical researchers.
lysobisphosphatidic acid metabolic process At A Glance
| GO ID | GO:2001311 |
|---|---|
| GO term | lysobisphosphatidic acid metabolic process |
| Ontology | biological_process |
| Synonym | LBPA metabolic process; bis(monoacylglycerol) hydrogen phosphate (BMP) metabolic process; lysobisphosphatidic acid metabolism |
| Major function | Metabolism of the lysosomal phospholipid LBPA/BMP, critical for lysosomal lipid degradation and membrane integrity |
| Related enzymes | CLN5 (synthase), PLD3/PLD4 (synthase), PLA2G15 (hydrolase) |
| Cellular location | Late endosomes and lysosomes |
| Associated diseases | Lysosomal storage disorders, neurodegeneration, Parkinson's disease |
What Is GO:2001311?
GO:2001311, lysobisphosphatidic acid metabolic process, is defined as the chemical reactions and pathways involving a lysobisphosphatidic acid. A lysobisphosphatidic acid is a lysophosphatidic acid having the unusual property of a phosphodiester moiety linked to positions sn-1 and sn1' of glycerol, and two additional fatty acids esterified to the glycerol head group. This process includes the biosynthesis, modification, and breakdown of LBPA/BMP within cellular compartments, primarily lysosomes.
Why Is lysobisphosphatidic acid metabolic process Important in Cell Biology?
GO:2001311 is important because LBPA/BMP is a key lysosomal phospholipid that enables the degradation of lipids and maintains lysosomal membrane integrity. Dysregulation of LBPA/BMP metabolism leads to lysosomal dysfunction, which is a hallmark of several neurodegenerative diseases and lysosomal storage disorders. The identification of CLN5 as a BMP synthase and PLA2G15 as a BMP hydrolase has provided direct genetic and biochemical links between this pathway and human disease, offering potential therapeutic targets. Moreover, LBPA/BMP has been implicated in autoimmune responses and coagulation through lipid presentation. Thus, studying GO:2001311 is essential for understanding lysosomal biology and developing treatments for related disorders.
• LBPA/BMP is essential for lysosomal lipid degradation and membrane dynamics.
• Mutations in CLN5, a BMP synthase, cause Batten disease (CLN5 disease), a neurodegenerative lysosomal storage disorder.
• PLA2G15 hydrolyzes BMP, and its inhibition ameliorates lysosomal disease phenotypes in models.
• PLD3 and PLD4 synthesize S,S-BMP, a stereoisomer critical for lysosomal function.
• Progranulin (GRN) loss-of-function, linked to frontotemporal dementia, causes lysosomal storage disorder that can be rescued by progranulin biologic, implicating LBPA/BMP metabolism.
• LRRK2 kinase activity regulates Parkinson's disease–relevant lipids at the lysosome, including BMP.
• LBPA/BMP presentation by the protein C receptor links coagulation with autoimmunity.
• LBPA/BMP may have evolutionary links to mitophagy and mitochondrial origin.
• Targeting LBPA/BMP metabolic enzymes offers therapeutic avenues for lysosomal disorders.
• CRISPR-based models are instrumental in dissecting the causal roles of LBPA/BMP metabolic genes.
What Happens During lysobisphosphatidic acid metabolic process?
Biosynthesis of LBPA/BMP by CLN5
In simple terms: The cell builds LBPA/BMP using a specific enzyme called CLN5.
CLN5, the gene product mutated in Batten disease, functions as a lysosomal bis(monoacylglycero)phosphate synthase. It catalyzes the formation of LBPA/BMP from precursor lipids, a step essential for lysosomal lipid degradation. Loss of CLN5 leads to reduced BMP levels and lysosomal dysfunction, highlighting its role in GO:2001311.
Synthesis of S,S-BMP by PLD3 and PLD4
In simple terms: Two related enzymes, PLD3 and PLD4, produce a specific form of BMP that the lysosome needs.
PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes. This stereospecific synthesis is critical for lysosomal function, and deficiency in these enzymes impairs lipid catabolism. Their role further defines the biosynthetic arm of GO:2001311.
Degradation of LBPA/BMP by PLA2G15
In simple terms: The enzyme PLA2G15 breaks down LBPA/BMP, and controlling this breakdown can help diseased cells.
PLA2G15 acts as a BMP hydrolase, and its targeting ameliorates lysosomal disease phenotypes. This hydrolytic step is part of the catabolic pathway in GO:2001311, balancing BMP levels. Inhibiting PLA2G15 may restore lysosomal function in disease models.
Regulation by LRRK2 kinase
In simple terms: The Parkinson's disease–linked kinase LRRK2 controls the levels of BMP and other lipids at the lysosome.
LRRK2 kinase activity regulates Parkinson's disease–relevant lipids at the lysosome, including BMP. This regulation links GO:2001311 to Parkinson's disease pathogenesis and suggests that LRRK2 inhibitors may modulate BMP metabolism.
Role in lysosomal lipid degradation and membrane integrity
In simple terms: LBPA/BMP helps the lysosome digest fats and keep its membrane in shape.
LBPA/BMP is required for lysosomal lipid degradation and membrane integrity, as reviewed in the BMP hypothesis. Its unique structure allows it to facilitate the action of lipid-degrading enzymes and maintain lysosomal homeostasis. Disruption of this process leads to lipid accumulation and cellular toxicity.
Key Genes Involved in GO:2001311 lysobisphosphatidic acid metabolic process
The following genes encode proteins directly involved in lysobisphosphatidic acid metabolic process (GO:2001311) or its regulation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CLN5 | Lysosomal BMP synthase | Mutations cause Batten disease; key enzyme in BMP synthesis |
| PLD3 | Synthesizes S,S-BMP | Deficiency impairs lysosomal lipid degradation |
| PLD4 | Synthesizes S,S-BMP | Deficiency impairs lysosomal lipid degradation |
| PLA2G15 | BMP hydrolase | Targeting ameliorates lysosomal disease |
| LRRK2 | Regulates BMP levels at lysosome | Parkinson's disease–relevant lipid regulation |
| GRN | Progranulin, involved in lysosomal function | Loss causes lysosomal storage disorder; rescue by progranulin biologic |
| PROCR | Protein C receptor, presents lipids | Links coagulation with autoimmunity via lipid presentation |
| ATG genes | Autophagy machinery | Potential evolutionary link to mitophagy and BMP |
| NPC1 | Lysosomal cholesterol transport | Implicated in lysosomal lipid metabolism |
| NPC2 | Lysosomal cholesterol transport | Implicated in lysosomal lipid metabolism |
| GBA | Glucocerebrosidase | Lysosomal enzyme linked to Parkinson's disease |
| SMPD1 | Acid sphingomyelinase | Lysosomal lipid metabolism |
| CTSD | Cathepsin D | Lysosomal protease involved in lipid degradation |
| LAMP1 | Lysosomal membrane protein | Marker for lysosomal integrity |
| LAMP2 | Lysosomal membrane protein | Marker for lysosomal integrity |
| TFEB | Transcription factor regulating lysosomal biogenesis | Master regulator of lysosomal genes |
| mTOR | Kinase regulating lysosomal function | Regulates autophagy and lysosomal metabolism |
How Is lysobisphosphatidic acid metabolic process Regulated?
LBPA/BMP metabolism is regulated at multiple levels. The transcription factor TFEB controls lysosomal biogenesis and may influence expression of BMP-metabolizing enzymes. LRRK2 kinase activity regulates BMP levels at the lysosome, linking Parkinson's disease–related signaling to this pathway. Additionally, the balance between synthesis by CLN5/PLD3/PLD4 and degradation by PLA2G15 determines steady-state BMP levels. Progranulin (GRN) deficiency alters lysosomal lipid metabolism, and progranulin biologic can rescue the phenotype, suggesting regulation by growth factor signaling.
lysobisphosphatidic acid metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CLN5 | Batten disease (CLN5 disease) | CLN5 knockout iPSCs or mouse models |
| GRN | Frontotemporal dementia | GRN knockout neurons; rescue with progranulin biologic |
| PLA2G15 | Lysosomal storage disorders | PLA2G15 knockout or inhibitor-treated cells |
| LRRK2 | Parkinson's disease | LRRK2 mutant knock-in neurons |
| PLD3/PLD4 | Lysosomal dysfunction | PLD3/PLD4 double knockout cells |
Lysosomal storage disorders and neurodegeneration
Defects in LBPA/BMP metabolism cause lysosomal storage disorders and neurodegeneration. Mutations in CLN5, a BMP synthase, lead to Batten disease, a fatal neurodegenerative disorder characterized by lysosomal accumulation. Progranulin (GRN) loss-of-function, linked to frontotemporal dementia, causes a lysosomal storage disorder that can be rescued by a brain-penetrant progranulin biologic, implicating BMP metabolism. Targeting PLA2G15, a BMP hydrolase, ameliorates lysosomal disease phenotypes, highlighting therapeutic potential.
Parkinson's disease
LRRK2 kinase activity regulates Parkinson's disease–relevant lipids at the lysosome, including BMP. This suggests that dysregulation of GO:2001311 contributes to Parkinson's disease pathogenesis, and modulating BMP levels may be beneficial.
Autoimmunity and coagulation
Lipid presentation by the protein C receptor links coagulation with autoimmunity, involving phospholipids such as LBPA/BMP. This connection indicates that LBPA/BMP metabolism may influence autoimmune responses and thrombotic risk.
Mitophagy and mitochondrial origin
LBPA/BMP has been hypothesized to play a role in mitophagy, with evolutionary links to mitochondrial origin. This suggests broader cellular functions beyond lysosomal degradation.
From lysobisphosphatidic acid metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CLN5 loss impair BMP synthesis? | CLN5 knockout cell line |
| Can PLA2G15 inhibition rescue lysosomal disease? | PLA2G15 knockout or point-mutation cells |
| What is the role of S,S-BMP stereochemistry? | PLD3/PLD4 knock-in with stereospecific mutations |
| How does LRRK2 regulate BMP levels? | LRRK2 knockout or kinase-dead knock-in neurons |
| Does progranulin rescue GRN deficiency? | GRN knockout neurons treated with progranulin biologic |
| Is BMP involved in autoimmunity? | PROCR knockout or overexpression models |
How to Study the lysobisphosphatidic acid metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Quantification of BMP species | Assessing enzyme function in KO/overexpression cells |
| CRISPR knockout screens | Gene essentiality for BMP metabolism | Identifying novel regulators |
| Fluorescence microscopy | Lysosomal morphology and lipid localization | Validating rescue of lysosomal phenotypes |
| RNA-seq | Transcriptional changes | Mapping regulatory networks |
| Proteomics | Protein abundance and interactions | Identifying BMP-binding proteins |
| Immunoblotting | Protein levels of CLN5, PLA2G15, etc. | Confirming knockout or overexpression |
| Enzymatic activity assays | Synthase or hydrolase activity | Measuring CLN5 or PLA2G15 function |
| CRISPR interference (CRISPRi) | Knockdown of gene expression | Titrating BMP enzyme levels |
Lipidomics and mass spectrometry
Lipidomics using mass spectrometry is essential to quantify LBPA/BMP species and their stereoisomers in cells and tissues. This method reveals changes in BMP levels upon genetic manipulation of CLN5, PLD3/4, or PLA2G15.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes required for LBPA/BMP metabolism and lysosomal function. Such screens have the power to uncover novel regulators of GO:2001311.
Fluorescence imaging and lysosomal markers
Imaging with lysosomal markers (e.g., LAMP1) and fluorescently labeled lipids can visualize LBPA/BMP distribution and lysosomal morphology. This is useful to assess rescue of lysosomal phenotypes.
Transcriptomics and proteomics
RNA-seq and proteomics can measure expression changes in genes and proteins involved in LBPA/BMP metabolism, such as TFEB targets. These approaches help define regulatory networks.
How CRISPR Can Be Used to Study GO:2001311 lysobisphosphatidic acid metabolic process
Knockout
CRISPR knockout of CLN5, PLD3/4, or PLA2G15 enables loss-of-function studies to determine their roles in LBPA/BMP metabolism. Knockout cells show altered BMP levels and lysosomal phenotypes, providing causal evidence.
Point Mutation
Point mutations can mimic disease-associated missense variants in genes like CLN5 or LRRK2 to study their impact on BMP metabolism. Such models help dissect catalytic versus non-catalytic functions.
Knock-in
Knock-in of tagged or stereospecific variants (e.g., S,S-BMP synthesis) allows precise tracking of LBPA/BMP and its interactors. This is useful for understanding stereochemistry and trafficking.
Overexpression
Overexpression of CLN5, PLD3/4, or PLA2G15 can elevate or deplete BMP levels, respectively, to test sufficiency and rescue. Overexpression models are valuable for therapeutic target validation.
How EDITGENE Supports lysobisphosphatidic acid metabolic process Research
Researchers studying lysobisphosphatidic acid metabolic process-related genes often need to determine whether a candidate gene is causally involved in BMP synthesis, degradation, or regulation. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models, enabling functional validation of genes in GO:2001311.
Contact EDITGENE today to design your custom CRISPR model for lysobisphosphatidic acid metabolic process research.
Frequently Asked Questions About lysobisphosphatidic acid metabolic process
What is lysobisphosphatidic acid metabolic process?
It is the set of chemical reactions and pathways involving lysobisphosphatidic acid (LBPA), also known as bis(monoacylglycero)phosphate (BMP), a unique lysosomal phospholipid.
What genes are involved in lysobisphosphatidic acid metabolic process?
Key genes include CLN5, PLD3, PLD4, PLA2G15, LRRK2, and GRN, which encode enzymes or regulators of BMP synthesis and degradation.
What is the GO ID for lysobisphosphatidic acid metabolic process?
The Gene Ontology ID is GO:2001311.
How is LBPA/BMP synthesized?
LBPA/BMP is synthesized by CLN5 and by PLD3/PLD4, which produce the S,S-stereoisomer essential for lysosomal lipid degradation.
How is LBPA/BMP degraded?
PLA2G15 acts as a BMP hydrolase, breaking down LBPA/BMP; its inhibition ameliorates lysosomal disease phenotypes.
What diseases are linked to LBPA/BMP metabolism?
Lysosomal storage disorders, Batten disease, frontotemporal dementia, Parkinson's disease, and autoimmune conditions have been linked to LBPA/BMP metabolism.
What is the role of CLN5 in Batten disease?
CLN5 is a BMP synthase; mutations cause Batten disease, leading to reduced BMP and lysosomal dysfunction.
How does LRRK2 regulate BMP?
LRRK2 kinase activity regulates Parkinson's disease–relevant lipids at the lysosome, including BMP.
What experimental models are used to study LBPA/BMP metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression cell models combined with lipidomics and imaging are commonly used.
Why is LBPA/BMP important for lysosomal function?
LBPA/BMP is required for lysosomal lipid degradation and membrane integrity, and its dysregulation leads to lipid accumulation and cellular toxicity.
Conclusion
GO:2001311, lysobisphosphatidic acid metabolic process, represents a critical lysosomal pathway with far-reaching implications for human health. The identification of CLN5 and PLD3/PLD4 as BMP synthases and PLA2G15 as a hydrolase has provided a molecular framework for understanding lysosomal lipid metabolism and its role in disease. Dysregulation of this pathway contributes to lysosomal storage disorders, neurodegeneration, and Parkinson's disease, making it a promising therapeutic target. Continued research using CRISPR-engineered models will further elucidate the mechanisms and enable the development of targeted therapies.
References
- 1. Medoh UN et al.. 2024. The Bis(monoacylglycero)-phosphate Hypothesis: From Lysosomal Function to Therapeutic Avenues.. Annu Rev Biochem 93(1):447-469 PMID: 38603559
- 2. Logan T et al.. 2021. Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic.. Cell 184(18):4651-4668.e25 PMID: 34450028
- 3. Medoh UN et al.. 2023. The Batten disease gene product CLN5 is the lysosomal bis(monoacylglycero)phosphate synthase.. Science 381(6663):1182-1189 PMID: 37708259
- 4. Nyame K et al.. 2025. PLA2G15 is a BMP hydrolase and its targeting ameliorates lysosomal disease.. Nature 642(8067):474-483 PMID: 40335701
- 5. Singh S et al.. 2024. PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes.. Cell 187(24):6820-6834.e24 PMID: 39423811
- 6. Degli Esposti M. 2024. Did mitophagy follow the origin of mitochondria?. Autophagy 20(5):985-993 PMID: 38361280
- 7. Maloney MT et al.. 2025. LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.. Mol Neurodegener 20(1):89 PMID: 40770658
- 8. Müller-Calleja N et al.. 2021. Lipid presentation by the protein C receptor links coagulation with autoimmunity.. Science 371(6534) PMID: 33707237
